Home
HelpTest ID: PRS8P Hereditary Prostate Cancer Panel, Varies
Ordering Guidance
Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.
Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.
Testing minors for adult-onset predisposition syndromes is discouraged by the American Academy of Pediatrics, the American College of Medical Genetics and Genomics, and the National Society of Genetic Counselors.
Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Specimen Required
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. For instructions for testing patients who have received a bone marrow transplant, call 800-533-1710.
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated
Additional Information: To ensure minimum volume and concentration of DNA is met, the preferred volume of blood must be submitted. Testing may be canceled if DNA requirements are inadequate.
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Molecular Genetics: Inherited Cancer Syndromes Patient Information (T519)
3. If not ordering electronically, complete, print, and send a Oncology Test Request (T729) with the specimen.
Useful For
Evaluating patients with a personal or family history suggestive of a hereditary prostate cancer syndrome
Establishing a diagnosis of a hereditary prostate cancer syndrome allowing for targeted cancer surveillance based on associated risks
Identifying genetic variants associated with increased risk for prostate cancer, allowing for predictive testing and appropriate screening of at-risk family members
Therapeutic eligibility with poly adenosine diphosphate-ribose polymerase (PARP) inhibitors based on certain gene alterations (eg, BRCA1, BRCA2)
Genetics Test Information
This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 18 genes associated with prostate cancer risk: ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM (copy number variants only), FANCA, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51B, RAD51C, RAD51D, and TP53. For more information see Method Description and Targeted Genes and Methodology Details for Hereditary Prostate Cancer Panel.
Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, familial screening, and genetic counseling for hereditary prostate cancer.
Method Name
Sequence Capture and Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Sanger Sequencing and/or Multiplex Ligation-Dependent Probe Amplification (MLPA)
Reporting Name
Hereditary Prostate Cancer PanelSpecimen Type
VariesSpecimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Varies | ||
Clinical Information
Hereditary prostate cancer accounts for approximately 5% to 10% of all prostate cancer cases and up to half of all early-onset prostate cancer cases.(1-3) Evaluation of the genes on this panel may be useful for families with a history of prostate cancer to determine cancer risk, surveillance recommendations, and targeted treatments (such as poly adenosine diphosphate-ribose polymerase [PARP] inhibitor therapy).(4,5)
The 2 most common hereditary prostate cancer syndromes are hereditary breast and ovarian cancer (HBOC) syndrome and Lynch syndrome.(3-5)
HBOC syndrome is caused by disease-causing variants in the BRCA1 and BRCA2 genes. Individuals with HBOC syndrome are also at increased risk for multiple cancer types, including prostate cancer.(5)
Lynch syndrome is caused by variants in the MLH1, MSH2, MSH6, and PMS2 mismatch-repair genes and deletions of the EPCAM gene. A subset of these patients present with prostate cancer.(3-5)
This panel includes other genes known to increase prostate cancer risk.(3-5) The risk of developing cancer associated with these syndromes varies. Some individuals with a disease-causing variant in one of these genes develop multiple primary cancers.(4)
The National Comprehensive Cancer Network and the American Cancer Society provide recommendations regarding the medical management of individuals with hereditary prostate cancer syndromes.(4,5)
Reference Values
An interpretive report will be provided.
Interpretation
All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(6) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.
Clinical Reference
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33
2. Lange EM, Salinas CA, Zuhlke KA, et al. Early onset prostate cancer has a significant genetic component. Prostate. 2012;72(2):147-156
3. Pritchard CC, Mateo J, Walsh M, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443-453. doi:10.1056/NEJMoa1603144
4. Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN guidelines insights: Prostate cancer, version 1.2021. J Natl Compr Canc Netw. 2021;19(2):134-143
5. Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(1):77-102
6. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424
Day(s) Performed
Varies
Report Available
14 to 21 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81162
81292
81295
81298
81307
81317
81319
81351
81403
81408
81479
81479 (if appropriate for government payers)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| PRS8P | Hereditary Prostate Cancer Panel | 100213-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 614803 | Test Description | 62364-5 |
| 614804 | Specimen | 31208-2 |
| 614805 | Source | 31208-2 |
| 614806 | Result Summary | 50397-9 |
| 614807 | Result | 82939-0 |
| 614808 | Interpretation | 69047-9 |
| 614809 | Resources | 99622-3 |
| 614810 | Additional Information | 48767-8 |
| 614811 | Method | 85069-3 |
| 614812 | Genes Analyzed | 48018-6 |
| 614813 | Disclaimer | 62364-5 |
| 614814 | Released By | 18771-6 |
mcl-moltechtestmenu; mcl-hereditarycancer